ライフサイエンスコーパス: or death

1 arction (1.08% versus 1.27%; HR, 0.85 [95% CI, 0.69-1.06]), or death (1.25% versus 1.47%; HR, 0.85 [95% CI, 0.70-1.03]).

2 as greater than or equal to two organ dysfunctions at day 7 or death by day 28.

3 sive care unit [ICU] admission or death vs no ICU admission or death).

4 outcome was defined as intensive care unit (ICU) admission or death.

5 versus patient outcome (intensive care unit [ICU] admission or death vs no ICU admission or death).

6 bnormality were predictors of intensive care unit admission or death.

7 Rates of acquired immunodeficiency syndrome (AIDS) or death on suppressive ART were calculated by PIR status.

8 Poor outcome was defined as invasive ventilation and/or death.

9 estinal bleeding who were at high risk for further bleeding or death, endoscopy performed within 6 hours after gastroente

10 er a mean follow-up of 3.7 +/- 2.9 years, there were 208 CV or death events.

11 the association between CT SVD biomarkers and either death, or death or dependence (modified Rankin Scale scores = 4-6) 1

12 men), of whom 39 (32.5%) experienced clinical deterioration or death.

13 tion, P = .02) were independent predictors of deterioration or death; as was C-reactive protein (OR, 2.1; 95% CI: 1.3, 3.

14 Safety outcomes included death, severe disability or death (mRS score 4-6), and symptomatic intracranial haemor

15 riables is strongly associated with severe COVID-19 disease or death and their early onset.

16 on of coronavirus disease 2019 (COVID-19) to severe disease or death are underexplored in U.S. cohorts.

17 imary outcomes were death and a composite of severe disease or death.

18 glomerular filtration rate (eGFR), end-stage renal disease, or death from renal causes), the individual components of thi

19 Deletion of either kinase domain or death domain in the T cell compartment reduced the T cell

20 trategy, reduced the risk of ischemic cardiovascular events or death from any cause over a median of 3.2 years.

21 with normal or high BMIs, rates of cure, treatment failure, or death did not vary by glycemic status.

22 Time to first fall or death over 2 years (primary outcome).

23 The rates of hospitalization or death were similar in the two groups.

24 nd >=25% decline from baseline, CKD-related hospitalization or death, or ESKD.

25 ult in a lower risk of severe neurodevelopmental impairment or death at 2 years of age.

26 t association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 t

27 The association between PXS score and subsequent intubation or death was assessed.

28 dmission CXR, the PXS score predicted subsequent intubation or death within three days of hospital admission (area under

29 The primary outcome was intubation or death, assessed in a time-to-event analysis.

30 lants, integrating such information can be critical in life or death decisions.

31 Graft loss or death occurred in about one third of recipients with DDD,

32 eatment failure (biopsy-proven acute rejection, graft loss, or death), delayed graft function, patient and graft survival

33 failure, local or regional recurrence, distant metastasis, or death from any cause, or was censored at the date of last

34 is associated with an increased risk of infectious outcomes or death in the ensuing 11months.

35 ilure was independently associated with recurrent pneumonia or death among patients with bacterial pneumonia following cl

36 months], respectively; hazard ratio for disease progression or death, 0.51 [95% CI, 0.39 to 0.66]; P < .001).

37 an, 7.4 months vs. 3.6 months; hazard ratio for progression or death, 0.34; 95% confidence interval, 0.25 to 0.47; P<0.00

38 ne doubled ORR-IC, reduced risk of intracranial progression or death by two thirds, and reduced risk of death by nearly h

39 The risk of intracranial progression or death was reduced by 68% in the tucatinib arm (hazard rati

40 The lower incidence of readmission or death in the chemoprevention group than in the placebo gro

41 ival (the time between randomisation and distant recurrence or death before recurrence), an exploratory endpoint in Short

42 atio (HR) of risk factors associated with rehospitalization or death.

43 % (95% CI, 32 to 41) with placebo (hazard ratio for relapse or death, 0.51; 95% CI, 0.42 to 0.61).

44 ovascular thrombolysis, the risk of the composite of stroke or death within 30 days was lower with ticagrelor-aspirin tha

45 The primary outcome was a composite of stroke or death within 30 days.

46 and interventional therapy in preventing symptomatic stroke or death.

47 of myocardial infarction, repeat revascularization, stroke, or death (termed major cardiovascular and cerebrovascular eve

48 costeroids, until treatment failure, unacceptable toxicity, or death.

49 nts were risk of the composite outcome of blood transfusion or death, and number of blood transfusions from randomisation

50 The primary outcome was mechanical ventilation or death by day 28.